Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,2135 SEK | -1,39% | -39,35% | -97,86% |
22/04 | Transcript : Xbrane Biopharma AB - Special Call | |
26/02 | Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024 |
Omzet 2024 * | 344 mln. 31,41 mln. 29,38 mln. | Omzet 2025 * | 680 mln. 62,18 mln. 58,16 mln. | Marktkapitalisatie | 327 mln. 29,85 mln. 27,92 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -101 mln. -9,23 mln. -8,64 mln. | Nettowinst (verlies) 2025 * | 104 mln. 9,51 mln. 8,89 mln. | EV/omzet 2024 * | 0,55 x |
Nettoliquiditeiten 2024 * | 138 mln. 12,65 mln. 11,83 mln. | Nettoschuld 2025 * | 116 mln. 10,58 mln. 9,9 mln. | EV/omzet 2025 * | 0,65 x |
K/w-verhouding 2024 * |
-1,58
x | K/w-verhouding 2025 * |
-
| Werknemers | 93 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,11% |
Recentste transcriptie over Xbrane Biopharma AB
1 dag | -1,39% | ||
1 week | -39,35% | ||
Lopende maand | -29,19% | ||
1 maand | -17,88% | ||
3 maanden | -86,57% | ||
6 maanden | -98,89% | ||
Lopend jaar | -97,86% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 01-01-15 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 11-01-21 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 09-10-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 01-01-15 | |
Director/Board Member | 70 | 01-01-15 | |
Director/Board Member | 53 | 01-01-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 0,2135 | -1,39% | 11 591 000 |
25-04-24 | 0,2165 | +4,09% | 37 415 150 |
24-04-24 | 0,208 | -3,48% | 49 579 610 |
23-04-24 | 0,2155 | -8,30% | 64 018 490 |
22-04-24 | 0,235 | -33,24% | 198 129 300 |
uitgestelde koers Nasdaq Stockholm, 26 april 2024 om 17:29 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-97,86% | 29,78 mln. | |
+1,51% | 42,75 mld. | |
+8,57% | 41,34 mld. | |
+49,22% | 41,61 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |